When was Embio founded?

Embio was founded in 1986 and raised its 1st funding round 17 years after it was founded.

Where is Embio located?

Embio is headquartered in Mumbai, India. It is registered at 501 SENTINEL, 5TH FLOOR, HIRANANDANI GARDENS, POWAI, MUMBAI, Maharashtra, India, 400076.

Which legal entities is Embio associated with?

Embio is associated with EMBIO LIMITED and 1 other.

How many employees does Embio have?

As of Aug 31, 2025, the latest employee count at Embio is 648.

Is Embio a funded company?

Embio is a funded company, having raised a total of $50.3M across 4 funding rounds to date. The company's 1st funding round was a $***** Unattributed round, raised on Sep 01, 2003.

How much is Embio worth?

The latest valuation of Embio is ₹***** as of May 26, 2026.

When was the latest funding round of Embio?

Embio's latest funding was a $***** PE round on May 27, 2026, with participation from 1 investor.

What is the annual revenue of Embio?

Annual revenue of Embio is between ₹100 Cr and ₹500 Cr as on Mar 31, 2025

Where does Embio rank among its competitors?

Embio ranks 5th amongst 959 active competitors, of which 38 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Embio, which secured $50M in May, 2026.

Who are the top competitors of Embio?

Embio's top competitors include Laurus Labs, Symbiotec and NGL Fine Chem. Among them, Embio secured the most recent funding round in May, 2026.

Embio - 2026 Company Profile, Team, Funding, Competitors & Financials

Embio is a late stage company based in Mumbai (India), founded in 1986 by Devesh Malladi. It operates as a Contract research and manufacturing company engaged in APIs and chiral intermediates. Embio has raised $50.3M in funding from UTI, with a current valuation of ₹*****. The company has 959 active competitors, including 38 funded and 137 that have exited. Its top competitors include companies like Laurus Labs, Symbiotec and NGL Fine Chem.

Company Details

Embio is engaged in manufacturing APIs and chiral intermediates. It has a portfolio of 24 chiral intermediates and 13 API products. Core competencies include fermentation/biotransformation, chiral chemistry, catalytic hydrogenation and handing controlled substance. It has an array of fermenters – 10L, 20L, 50L, 100L, 500L, 1000L, 2000L, 4000L for products of high value and low volume such as enzymes, APIs etc. for satisfying contract manufacturing requirements of its clients. Its manufacturing facility is approved by US-FDA, TGA, WHO-GMP and KFD. It has been complimented by DEA for adhering to documentation systems for controlled substance regulations. It has also been accredited with USP mark and certificate for Pseudoephedrine HCL.

Website: embio.co.in
Registered Address: 501 SENTINEL, 5TH FLOOR, HIRANANDANI GARDENS, POWAI, MUMBAI, Maharashtra, India, 400076

Key Metrics

Founded Year

1986

Location

Mumbai, India

Stage

Late Stage

Total Funding

$50.3M in 4 rounds

Latest Funding Round

PE, May 27, 2026, $*****

Post Money Valuation

₹***** as on May 26, 2026

Investors

UTI & 27 more

Ranked

5^th among 959 active competitors

Annual Revenue

₹100 - ₹500 Cr as on Mar 31, 2025

Employee Count

648 as on Aug 31, 2025

Similar Companies

Laurus Labs & 1223 more

View Embio's full profile

Embio is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
MALLADI INDUSTRIES PRIVATE LIMITED CIN: U24230MH2004PTC144351 , India, Amalgamated	Feb 04, 2004	₹100 - ₹500 Cr (As on Mar 31, 2017)	-
EMBIO LIMITED CIN: U24110MH1986PLC038680 , India, Active	Jan 20, 1986	₹100 - ₹500 Cr (As on Mar 31, 2025)	648 (As on Aug 31, 2025)

Embio has raised a total funding of $50.3M over 4 rounds. Its first funding round was on Sep 01, 2003. Its latest funding round was a PE round on May 27, 2026 for $*****. 1 investor participated in its latest round. Embio has 10 institutional investors and 18 angel investors.

Here is the list of recent funding rounds of Embio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 27, 2026	7900969	PE	9820866	1983047	8635174	6955156
Oct 24, 2018	5524269	Unattributed	6991746	5027705	5723460	4433353
Aug 26, 2009	5456908	Unattributed	3165884	7409160	5397230	9066704

Access funding benchmarks and valuations. Sign up today!

View details of Embio's funding rounds and investors

The founders of Embio is Devesh Malladi.

Here are the details of Embio's key team members:

Devesh Malladi: Managing Director of Embio. They serve on the board of 1 company.
Contact Info: 1 email address

Embio's Board of Directors

Embio's board has 6 active members. RAJENDRA PRABHU KAMALAKANT and Devesh Malladi are part of team and Madhusudan Rao, Ajit Tekchand Vaswani, HANUMANT AVADHANI MALLADI and JAYANT NARAYAN GODBOLE are independent board members.

Here is the list of Embio's board of directors:

Name	Type	Representing	Status	Duration
RAJENDRA PRABHU KAMALAKANT	Team	-	Current	17y 11m
Devesh Malladi	Team	-	Current	18y 11m
Madhusudan Rao	Independent board member	-	Current	9y 1m
ebwmymo	Independent board member	-	Current	7y 1m
uvrkqqr	Independent board member	-	Current	4y 2m
ghiiimj	Independent board member	-	Current	3y 4m
yoaxiru	Independent board member	-	Past	3y 7m

View details of Embio's Founder profiles and Board Members

Embio's employee count trend

Embio has 648 employees as of Aug 25. The total employee count is 6.0% more than what it was in Aug 24. Here is Embio's employee count trend over the years:

Uncover Embio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Embio include Laurus Labs, Symbiotec and NGL Fine Chem. Here is the list of Top 10 competitors of Embio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Laurus Labs 2005, Hyderabad (India), Public	Pharmaceutical and biotechnology company	$230M	F-Prime Capital, IKP Knowledge Park & 3 others	78/100
2nd	Symbiotec 2002, Indore (India), Acquired	Manufacturer of non sterile steroid hormone based APIs and intermediates	$61.1M	Franklin Templeton Investments, Actis & 21 others	64/100
3rd	NGL Fine Chem 1981, Mumbai (India), Public	CDMO specializing in multi stage organic synthesis of generic APIs and fine chemicals	-	-	59/100
4th	Neuland 1984, Hyderabad (India), Public	Manufacturer of active pharmaceutical ingredients (APIs) and peptides	-	India Capital Growth, InvAscent & 1 others	58/100
5th	Embio 1986, Mumbai (India), Late Stage	Contract research and manufacturing company engaged in APIs and chiral intermediates	$50.3M	True North, UTI & 26 others	58/100
6th	Snapdragon Chemistry 2014, Cambridge (United States), Acquired	CDMO providing API development, manufacturing, and analytical services	-	Asymchem, C2I Accelerator & 1 others	55/100
7th	SeQuent 2002, Bengaluru (India), Acquired	APIs Manufacturer	-	Nepean Capital, Thecarlylegroup.fr & 2 others	54/100
8th	ST PHARM 2008, Siheung si (South Korea), Public	CDMO providing oligonucleotide, mRNA, and small molecule services	-	E&Investment, Synergy IB investment & 1 others	54/100
9th	Hikal 1988, Mumbai (India), Public	Traditional company offering contract research, custom synthesis & custom manufacturing of APIs and intermediates	-	IFC	53/100
10th	Enaltec Labs 2006, Mumbai (India), Acquired	Provider of complex small-volume technology-driven pharmaceutical products	$8.56M	InvAscent, Medtech Global & 7 others	52/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Embio's competitors? Click here to see the top ones

Founders (largest shareholder) own 79.26%, Funds own 14.43%, Enterprises own 2.89% and Other People own 3.42%. The net worth of Embio's founders is INR 1,370Cr as of May 26, 2026.

Shareholders Name	Post Round Holding %	Net worth	Cumulative Investment	Realised Returns	Unrealised Returns	Return Multiple
Founder	79.26%	1,370Cr	1550678	5599810	1177455	5097957
Devesh Malladi	0	0	0	0	0	0
Fund	14.43%	250Cr	1120284	9326373	2391462	2160374
True North	683295	654277	827069	305080	741766	400040
Enterprise	2.89%	50Cr	76	65	61	28
Other People	3.42%	59.3Cr	593	155	138	961
Total	100.00%	1,730Cr	3931802	4676102	9739246	2773596